Immune hemolytic anemia associated with sulindac

Area of Science:

• Hematology
• Pharmacology
• Immunology

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
• Sulindac is an NSAID known to cause various adverse reactions.
• Acute hemolytic anemia has not been previously reported as an adverse effect of sulindac.

Observation:

• Two patients presented with severe immune hemolytic anemia.
• One of the cases associated with sulindac was fatal.
• In vitro studies were conducted to investigate the potential link.

Findings:

• Evidence suggests sulindac may induce acute immune hemolytic anemia.
• Antibodies against sulindac and its metabolites were detected in patient serum.
• This indicates an autoimmune response triggered by the drug.

Implications:

• This finding expands the known adverse reaction profile of sulindac.
• Clinicians should consider sulindac as a potential cause of drug-induced hemolytic anemia.
• Further research is warranted to elucidate the mechanisms of sulindac-induced hemolytic anemia.